Overexpression of E2F1 in clear cell renal cell carcinoma: A potential impact of erroneous regulation by thyroid hormone nuclear receptors

Thyroid

Volumn 17, Issue 11, 2007, Pages 1039-1048

  Turowska, Olga ^a   Nauman, Alicja ^a   Pietrzak, Maciej ^b   Popławski, Piotr ^a   Master, Adam ^a   Nygard, Maria ^c   Bondesson, Maria ^c   Tanski, Zbigniew ^d   Puzianowska Kuznicka, Monika ^a,b  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d Specialistic Hospital   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; LIOTHYRONINE; THYROID HORMONE RECEPTOR; TRANSCRIPTION FACTOR E2F1;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLEAR CELL CARCINOMA; DISEASE FREE INTERVAL; DNA BINDING; FEMALE; GENE OVEREXPRESSION; HORMONAL REGULATION; HORMONE SENSITIVITY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LIOTHYRONINE BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; RECEPTOR INTRINSIC ACTIVITY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DNA; E2F1 TRANSCRIPTION FACTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS (GENETICS); RECEPTORS, THYROID HORMONE; RNA, MESSENGER; THYROID HORMONE RECEPTORS ALPHA; THYROID HORMONE RECEPTORS BETA; TRIIODOTHYRONINE;

EID: 36749004292     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2007.0075     Document Type: Article

References (41)

1. Puzianowska-Kuznicka M, Pietrzak M, Turowska O, Nauman A 2006 Thyroid hormones and their receptors in the regulation of cell proliferation. Acta Biochim Pol 53:641-650.
2. Carr FE, Wong NCW 1994 Characteristics of a negative thyroid hormone response element. J Biol Chem 269:4175-4179.
3. Attwooll C, Lazzerini Denchi E, Helin K 2004 The E2F family: specific functions and overlapping interests. EMBO J 23:4709-4716.
4. Nygard M, Wahlstrom GM, Gustafsson MV, Tokumoto YM, Bondesson M 2003 Hormone-dependent repression of the E2F-1 gene by thyroid hormone receptors. Mol Endocrinol 17:79-92.
5. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC 1999 Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98:859-869.
6. Mundle SD, Saberwal G 2003 Evolving intricacies and implications of E2F1 regulation. FASEB J 17:569-574.
7. Helin K 1998 Regulation of cell proliferation by the E2F transcription factors. Curr Opin Genet Dev 8:28-35.
8. Geng Y, Eaton EN, Picon M, Roberts JM, Lundberg AS, Gifford A, Sardet C, Weinberg RA 1996 Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene 12:1173-1180.
9. Nevins JR 2001 The Rb/E2F pathway and cancer. Hum Mol Genet 10:699-703.
10. Bell LA, Ryan KM 2004 Life and death decisions by E2F-1. Cell Death Differ 11:137-142.
11. Tsantoulis PK, Gorgoulis VG 2005 Involvement of E2F transcription factor family in cancer. Eur J Cancer 41:2403-2414.
12. Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, Vousden KH 1998 p14ARF links the tumour suppressors RB and p53. Nature 395:124-125.
13. Stiewe T, Putzer BM 2000 Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 26:464-469.
14. Moroni MC, Hickman ES, Lazzerini Denchi E, Caprara G, Colli E, Cecconi F, Muller H, Helin K 2001 Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol 3:552-558.
15. Nahle Z, Polakoff J, Davuluri RV, McCurrach ME, Jacobson MD, Narita M, Hang MQ, Lazebnik Y, Bar-Sagi D, Lowe SW 2002 Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol 4:859-864.
16. Seville LL, Shah N, Westwell AD, Chan WC 2005 Modulation of pRB/E2F functions in the regulation of cell cycle and in cancer. Curr Cancer Drug Targets 5:159-170.
17. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. 1999 Rising incidence of renal cell cancer in the United States. JAMA 281:1628-1631.
18. van den Berg A, Buys CH 1997 Involvement of multiple loci on chromosome 3 in renal cell cancer development. Genes Chromosomes Cancer 19:59-76.
19. van den Berg A, Dijkhuizen T, Draaijers TG, Hulsbeek MM, Maher ER, van den Berg E, Storkel S, Buys CH 1997 Analysis of multiple renal cell adenomas and carcinomas suggests allelic loss at 3p21 to be a prerequisite for malignant development. Genes Chromosomes Cancer 19:228-232.
20. Foster K, Crossey PA, Cairns P, Hetherington JW, Richards FM, Jones MH, Bentley E, Affara NA, Ferguson-Smith MA, Maher ER 1994 Molecular genetic investigation of sporadic renal cell carcinoma: analysis of allele loss on chromosomes 3p, 5q, 11p, 17, and 22. Br J Cancer 69:230-234.
21. Pachucki J, Ambroziak M, Tanski Z, Luczak J, Nauman J, Nauman A 2001 Type I 50-iodothyronine deiodinase activity and mRNA are remarkably reduced in renal clear cell carcinoma. J Endocrinol Invest 24:253-261.
22. Puzianowska-Kuznicka M, Nauman A, Madej A, Tanski Z, Cheng S, Nauman J 2000 Expression of thyroid hormone receptors is disturbed in human renal clear cell carcinoma. Cancer Lett 155:145-152.
23. Kamiya Y, Puzianowska-Kuznicka M, McPhie P, Nauman J, Cheng SY, Nauman A 2002 Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma. Carcinogenesis 23:25-33.
24. Madej A, Puzianowska-Kuznicka M, Tanski Z, Nauman J, Nauman A 2003 Vitamin D receptor binding to DNA is altered without the change in its expression in human renal clear cell cancer. Nephron Exp Nephrol 93e:e150-e157.
25. Neuman E, Flemington EK, Sellers WR, Kaelin WG Jr. 1994 Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter. Mol Cell Biol 14:6607-6615.
26. Johnson DG, Ohtani K, Nevins JR 1994 Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev 8:1514-1525.
27. Puzianowska-Kuznicka M, Krystyniak A, Madej A, Cheng S-Y, Nauman J 2002 Functionally impaired thyroid hormone receptor mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab 87:1120-1128.
28. Lin KH, Shieh HY, Chen SL, Hsu HC 1999 Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol Carcinog 26:53-61.
29. McCabe CJ, Gittoes NJ, Sheppard MC, Franklyn JA 1999 Thyroid receptor alpha1 and alpha2 mutations in nonfunctioning pituitary tumors. J Clin Endocrinol Metab 84:649-653.
30. Cheng SY 2003 Thyroid hormone receptor mutations in cancer. Mol Cell Endocrinol 213:23-30.
31. Ting YT, Bhat MK, Wong R, Cheng S 1997 Tissue-specific stabilization of the thyroid hormone beta1 nuclear receptor by phosphorylation. J Biol Chem 272:4129-4134.
32. Tzagarakis-Foster C, Privalsky ML 1998 Phosphorylation of thyroid hormone receptors by protein kinase A regulates DNA recognition by specific inhibition of receptor monomer binding. J Biol Chem 273:10926-10932.
33. Chen SL, Chang YJ, Wu YH, Lin KH 2003 Mitogen-activated protein kinases potentiate thyroid hormone receptor transcriptional activity by stabilizing its protein. Endocrinology 144:1407-1419.
34. Kenessey A, Sullivan EA, Ojamaa K 2006 Nuclear localization of protein kinase C-alpha induces thyroid hormone receptor-alpha1 expression in the cardiomyocyte. Am J Physiol Heart Circ Physiol 290:H381-H389.
35. Lin HY, Hopkins R, Cao HJ, Tang HY, Alexander C, Davis FB, Davis PJ 2005 Acetylation of nuclear hormone receptor superfamily members: thyroid hormone causes acetylation of its own receptor by a mitogen-activated protein kinase-dependent mechanism. Steroids 70:444-449.
36. Salon C, Eymin B, Micheau O, Chaperot L, Plumas J, Brambilla C, Brambilla E, Gazzeri S 2006 E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific down-regulation of c-FLIP(short). Cell Death Differ 13:260-272.
37. Bramis J, Zacharatos P, Papaconstantinou I, Kotsinas A, Sigala F, Korkolis DP, Nikiteas N, Pazaiti A, Kittas C, Bastounis E, Gorgoulis VG 2004 E2F-1 transcription factor immunoexpression is inversely associated with tumor growth in colon adenocarcinomas. Anticancer Res 24:3041-3047.
38. Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, McDonnell TJ, Shi X, Rao JS, Levin VA, Kyritsis AP 1998 Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med 4:685-690.
39. Alonso MM, Fueyo J, Shay JW, Aldape KD, Jiang H, Lee OH, Johnson DG, Xu J, Kondo Y, Kanzawa T, Kyo S, Bekele BN, Zhou X, Nigro J, McDonald JM, Yung WK, Gomez-Manzano C 2005 Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. J Natl Cancer Inst 97:1589-1600.
40. Lu Z, Luo RZ, Peng H, Huang M, Nishmoto A, Hunt KK, Helin K, Liao WS, Yu Y 2006 E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. Oncogene 25:230-239.
41. Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, Kletsas D, Asimacopoulos PJ, Agnantis N, Kittas C, Papavassiliou AG 2002 Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol 198:142-156.